Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 4Pain, Postoperative 2Vesico-Ureteral Reflux 1Uterine Neoplasms 1Ureteral Neoplasms 1Peritoneal Cancer 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Neuralgia 1Nephrolithiasis 1Neoplasms 1Malignant Neoplasms of Female Genital Organs 1Lung Neoplasms 1Leiomyoma 1Kidney Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Digestive System Diseases 1Breast Cancer Female 1Abdominal Cancer 1

Interventions

Paclitaxel 79Carboplatin 64Bevacizumab 33liposomal doxorubicin 29Topotecan 28Gemcitabine 25Cisplatin 19olaparib 18Drug Therapy 12Doxorubicin 12Taxes 11niraparib 9Docetaxel 6CP protocol 6Trabectedin 5Hyperthermic Intraperitoneal Chemotherapy 5Etoposide 5Cyclophosphamide 51-dodecylpyridoxal 5rucaparib 4pembrolizumab 4avelumab 4atezolizumab 4Immunoglobulin G 4Ifosfamide 4Disulfides 4Dexamethasone 4Chemotherapy, Adjuvant 4trebananib 3fluzoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Ovarian Neoplasms × Bupivacaine × Clear all
NCT04849858 2024-08-23

Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

University of California, Irvine

Phase 3 Terminated
13 enrolled
Gynecologic

Leiomyoma, Ovarian Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡